BIOMARIN PHARMACEUTICAL INC 8K

BioMarin will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in milestones to gain ALE1, a potential first oral therapy for hypophosphatasia, with non-ALE1 assets and employees spun out before closing and modest 2026 earnings dilution expected.

BioMarin Pharmaceutical Inc. announced that it has entered into a definitive agreement to acquire Alesta Therapeutics in order to obtain ALE1, an orally active small-molecule therapy candidate that could become the first oral treatment for hypophosphatasia (HPP), for an upfront payment of $275 million in cash plus up to $215 million in development and regulatory milestone payments. Prior to closing, Alesta will spin out all non-ALE1 assets into a new entity and transfer all Alesta employees to that spinout, so no employees will join BioMarin in connection with the deal. The transaction, approved by both companies’ boards and expected to close this quarter subject to customary conditions, will be funded with BioMarin’s cash on hand, incorporated into updated 2026 guidance after closing, and is anticipated to be modestly dilutive to BioMarin’s 2026 financial results excluding the upfront consideration, while strategically strengthening its early-stage pipeline and rare disease market presence through ALE1’s ongoing Phase 1/2a program for HPP.

Filing Facts

CIK

1048477

Ticker

BMRN

Form

8K

Source Type

fda

Accession

0001193125-26-354780

Alert Tier

8